Patents and Postapproval Batch Testing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Patents and Postapproval Batch Testing
Can postapproval FDA filings immunize pharma companies from patent lawsuits?

Pharmaceutical Technology
Volume 36, Issue 12

Whether one can reconcile these two decisions, the Supreme Court could very well end up resolving the issue. GSK filed a petition for certiorari asking the Supreme Court to clarify "[w]hether the Federal Circuit's interpretation of 271(e)(1) [in Classen], which arbitrarily restricts the safe harbor to preapproval activities, is faithful to statutory text that contains no such limitation, and decisions of this Court rejecting similar efforts to impose extratextual limitations on the statute" (14). The Supreme Court may welcome the opportunity to provide its guidance on the scope of Hatch–Waxman's safe harbor—an issue the high court has addressed twice before (15)—especially in light of this seeming inconsistency in Federal Circuit precedent in this area of the law.

Kevin Murphy is a partner with the New York office of Frommer Lawrence and Haug LLP. Andrew Nason is an associate in the DC office of the same firm,
. The views expressed in this article are solely those of the authors and are not to be attributed to Frommer Lawrence and Haug LLP or any of its clients.


1. Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661, 669-71 (1990).

2. 35 U.S.C. � 271(e)(1) (2012).

3. 659 F.3d 1057, 1060, 1070 (Fed. Cir. 2011).

4. Ibid. at 1060.

5. Ibid. at 1070-72.

6. Ibid. at 1070.

7. 686 F.3d 1348 (Fed. Cir. 2012).

8. Ibid. at 1351.

9. Ibid. at 1353.

10. Ibid. at 1352-53.

11. Ibid. at 1354-55.

12. Ibid. at 1361-76.

13. Ibid. at 1357-58.

14. Petition for a Writ of Certiorari at i., GlaxoSmithKline v. Classen Immunotherapies, Inc., No. 11-1078 (U.S. Feb. 28, 2012).

15. Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 206-07 (2005); Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here